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Abstract
Background: Fibrosis may be considered the hallmark of systemic sclerosis (SSc), the end stage triggered by
different pathological events. Transforming growth factor-β (TGF-β) and platelet-derived growth factor BB
(PDGF-BB) are profibrotic molecules modulating myofibroblast differentiation and proliferation, respectively.
There is evidence linking CD248 with these two molecules, both highly expressed in patients with SSc, and
suggesting that CD248 may be a therapeutic target for several diseases. The aim of this work was to evaluate
the expression of CD248 in SSc skin and its ability to modulate SSc fibrotic process.
Methods: After ethical approval was obtained, skin biopsies were collected from 20 patients with SSc and 10
healthy control subjects (HC). CD248 expression was investigated in the skin, as well as in bone marrow mesenchymal
stem cells (MSCs) treated with TGF-β or PDGF-BB, by immunofluorescence, qRT-PCR, and Western blotting. Finally, in
SSc-MSCs, the CD248 gene was silenced by siRNA.
Results: Increased expression of CD248 was found in endothelial cells and perivascular stromal cells of SSc skin. In
SSc-MSCs, the levels of CD248 and α-smooth muscle actin expression were significantly higher than in HC-MSCs. In
both SSc- and HC-MSCs, PDGF-BB induced increased expression of Ki-67 when compared with untreated cells but was
unable to modulate CD248 levels. After CD248 silencing, both TGF-β and PDGF-BB signaling were inhibited
in SSc-MSCs.
Conclusions: CD248 overexpression may play an important role in the fibrotic process by modulating the
molecular target, leading to perivascular cells differentiation toward myofibroblasts and interfering with its
expression, and thus might open a new therapeutic strategy to inhibit myofibroblast generation during SSc.
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Background
CD248 (also known as endosialin or tumor endothelial
marker 1) is a transmembrane receptor whose known li-
gands are fibronectin and type I/IV collagen. It is widely
expressed on mesenchymal cells during embryonic life
and is required for proliferation and migration of peri-
cytes and fibroblasts [1]. Although CD248 expression is
dramatically reduced during adult life, it may be upregu-
lated during specific conditions such as malignancy, in-
flammation, and fibrosis [2–4]. It is well known that
CD248 is expressed on the surface of cells of mesenchy-
mal origin, including tumor-associated pericytes and ac-
tivated fibroblasts, which are thought to play a key role
in the development of tumor neovascular networks and
stromal interaction [1]. The interruption of endosialin
function, with antibody blockade or genetic knockouts,
negatively affects tumor growth and angiogenesis in nu-
merous cancer types [5–7]. Furthermore, in the experi-
mental model of kidney fibrosis after unilateral ureteral
obstruction (UUO), CD248−/− mice display downregula-
tion of myofibroblast proliferation, thus decreasing the
kidney fibrosis [8]. These biologic effects, in cancer and
in reparative response, may be related to the ability of
CD248 to modulate many signaling pathways involved
in both cancer development and tissue repair, including
platelet-derived growth factor BB (PDGF-BB), trans-
forming growth factor-β (TGF-β), and Notch receptor
protein [9]. Under normal conditions, pericytes that
expressed high levels of CD248 were able to proliferate,
responding to PDGF-BB stimulation [9], and higher ex-
pression of CD248 is required for imparting fibroblast
sensitivity to the effects of TGF-β [10].
Owing to its multifunctional activities modulating in-
nate immunity, cell proliferation, and vascular homeo-
stasis [9, 11], CD248 may be considered a potential
therapeutic target for several diseases [12], and currently,
the results of a first-in-human, open-label, phase I study
recruiting patients with extracranial solid tumors who
failed standard chemotherapy and were treated with a
biologic therapy targeting CD248 have been published,
confirming the therapy’s safety and a positive impact on
different cancers [13].
Systemic sclerosis (SSc) is a connective tissue disease
of unknown etiology with multiorgan involvement and
heterogeneous clinical manifestations. The hallmark of
early SSc is endothelial involvement, whereas later stages
are characterized by an excessive accumulation of extra-
cellular matrix (ECM), resulting in extended fibrosis in
skin and internal organs [14, 15]. In the last few years, it
has been clarified that endothelial cells (ECs) and peri-
cytes, after injury, may differentiate toward myofibro-
blasts, which are committed to producing increased
amounts of collagen [16–18], and this process has been
proposed as a key pathogenic mechanism in SSc.
Several polypeptide mediators are involved in fibrosis
during SSc, such as TGF-β and PDGF-BB. The latter is a
potent pro-proliferative signal for mesenchyme-derived
cells, including myofibroblasts [19, 20], whereas TGF-β
primarily promotes myofibroblast activation, α-smooth
muscle actin (α-SMA) expression, and collagen depos-
ition [16, 21–26]. Interestingly, CD248 modulates both
these pathways because of CD248 is required for impart-
ing fibroblast sensitivity to the effects of TGF-β [9] and
is crucial for optimal migratory response of activated fi-
broblasts to PDGF-BB [19].
The goal of this work is to investigate the expression
of CD248 in skin perivascular stromal cells from patients
with SSc and its ability in mediating pericyte differenti-
ation toward myofibroblasts. Although the role of
CD248 in the pathogenesis of SSc has not yet been
established, its potential role in controlling vessel regres-
sion and fibrosis makes this molecule a potential thera-
peutic target in a clinical setting, different from cancer,
and in which an effective therapeutic approach to pre-
vent fibrosis is still an important unmet need.
Methods
Patients, control subjects, and skin biopsies
Full-thickness biopsy samples measuring 2 × 0.5 cm iso-
lated from excisional biopsy were obtained from clinic-
ally involved skin of one-third of the distal forearm of
patients with diffuse SSc according to the classification
of LeRoy and colleagues [27]. All patients fulfilled the
2013 classification criteria for SSc [28]. Skin with a
modified Rodnan skin score [29] ≥ 1 was considered to
be clinically involved.
To be sure that 50% of our patients were in a very
early phase of SSc, considering that the term early cur-
rently refers to an undifferentiated connective tissue dis-
ease at higher risk of developing into scleroderma, as
suggested by the pivotal study of Koening et al. [30],
more than to a time frame from the beginning of the
disease, we further divided our patients into two subsets:
patients fulfilling the classification criteria in less than 1
year from the onset of Raynaud’s phenomenon (ear-
ly-onset subset [EOS], n = 10) and all the others (long--
standing subset [LSS], n = 10). Skin samples from the
same region of ten age- and sex-matched healthy control
subjects (HC) who underwent a surgical treatment for
trauma were used for comparison. All patients with SSc
underwent a 20-day washout from any immunosuppres-
sive treatment and 1 month from intravenous prosta-
noids before skin biopsy was performed. During this
period, only proton pump inhibitors and clebopride were
allowed. Patients who could not undergo therapeutic
washout owing to severe organ complications were not
enrolled in the study. Biopsies were taken after informed
consent was obtained, and the study was approved by
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our local ethics committee (ASL Avezzano Sulmona
L’Aquila, protocol number 015408/17). Demographic
and clinical characteristics of the patients are shown
in Table 1. Each biopsy sample was divided into spec-
imens for immunofluorescence (IF) and qRT-PCR. For
IF, the specimens were fixed in 10% buffered forma-
lin, dehydrated in graded alcohol series, and embed-
ded in paraffin. Specimens used for qRT-PCR analyses
were immediately immersed in liquid nitrogen and
stored at − 80 °C until use.
Immunofluorescence
The IF analysis was performed on paraffin sections
(thickness 3 μm) using a conjugated anti-CD248 antibody
(Novus Biologicals, Littleton, CO, USA). Antigen retrieval
was carried out using Dako Target Retrieval solution
(Agilent Technologies, Santa Clara, CA, USA). Vascula-
ture pericytes were highlighted using a Cy3-conjugated
anti-α-SMA antibody (Sigma-Aldrich, St. Louis, MO,
USA) and EC using unconjugated anti–von Willebrand
factor (vWF) antibody (Dako, Glostrup, Denmark). The
immunoreaction was revealed using secondary antibody
(Alexa Fluor; Life Technologies, Carlsbad, CA, USA).
Cell nuclei were visualized using 4′,6-diamidino-2-
phenylindole. Fluorescence was analyzed using a
BX53 fluorescence microscope (Olympus, Center Val-
ley, PA, USA). The intensity of fluorescence was mea-
sured using ImageJ software (National Institutes of
Health, Bethesda, MD, USA).
Isolation, culture, and immunophenotyping of
mesenchymal stem cells
After approval was provided by the local ethics committee
(ASL Avezzano Sulmona L’Aquila) and written informed
consent was obtained from patients, bone marrow was ob-
tained by aspiration from the posterior superior iliac crest
from the patients enrolled in the study. Samples of mesen-
chymal stem cells (MSC) from bone marrow donors were
used as a control. MSC were obtained and expanded from
both the subsets of five EOS and five LSS patients, as pre-
viously described [25]. Third-passage MSC were analyzed
for the surface expression of MSC antigens (CD45, CD73,
CD90, CD34, CD79a, PDGF receptor-β) and pericyte
markers (α-SMA, SM22α, NG2, desmin, RGS5) by flow
Table 1 Clinical and demographic features of the 20 patients with diffuse systemic sclerosis
Sex/age (yr) Disease duration at skin
biopsy (yr from RP)
mRSS/score at
skin biopsy
Autoantibodies ILD PAH SRC RP DU
95% F 50% EOS
50% LSS
100% ANA/Scl70 25% ILD 15% PAH; 0% SCR 100% RP 30% DU
F/45 < 1 10/2 ANA/Scl-70 No No No Yes No
F/22 < 1 13/1 ANA/Scl-70 No No No Yes Yes
F/31 < 1 08/2 ANA/Scl-70 No No No Yes No
F/38 < 1 09/2 ANA/Scl-70 No Yes No Yes Yes
M/20 < 1 11/1 ANA/Scl-70 No No No Yes No
F/40 < 1 10/2 ANA/Scl-70 No No No Yes No
F/31 < 1 10/1 ANA/Scl-70 No No No Yes No
F/21 < 1 09/1 ANA/Scl-70 No No No Yes No
F/31 < 1 14/1 ANA/Scl-70 No No No Yes No
F/42 < 1 16/2 ANA/Scl-70 Yes No No Yes No
F/45 4 17/2 ANA/Scl-70 No No No Yes No
F/21 5 15/1 ANA/Scl-70 No No No Yes No
F/30 6 18/2 ANA/Scl-70 No Yes No Yes Yes
F/33 4 13/2 ANA/Scl-70 Yes No No Yes No
F/34 4 12/1 ANA/Scl-70 No No No Yes Yes
F/40 4 10/2 ANA/Scl-70 Yes Yes No Yes No
M/26 6 10/2 ANA/Scl-70 Yes No No Yes Yes
F/21 4 11/1 ANA/Scl-70 No No No Yes No
F/30 3 12/2 ANA/Scl-70 Yes No No Yes Yes
F/33 4 12/1 ANA/Scl-70 No No No Yes No
Abbreviations: EOS Early-onset subset, LSS Long-standing subset, RP Raynaud’s phenomenon, mRSS Modified Rodnan skin score (maximum possible score 51), ILD
Interstitial lung disease, ANA Antinuclear antibodies, Scl-70 Antitopoisomerase, PAH Pulmonary arterial hypertension, SRC Scleroderma renal crisis, DU Digital ulcers
The internal organ involvement is referred to the time of biopsies
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cytometry (FACScan; BD Biosciences, San Jose, CA, USA)
as previously described [25] (data not shown).
MSC response to PDGF-BB and TGF-β
To establish the optimal concentration of PDGF-BB and
TGF-β molecules, in our system, a dose-response curve
was created, using P3 cells of one HC and one patient
and evaluating the Ki-67 and α-SMA messenger RNA
(mRNA) expression. Each experiment was performed in
triplicate (data not shown). Both SSc-MSC and HC-
MSC were cultured for 7 days in 1% FBS medium sup-
plemented with selected doses of 10 ng/ml PDGF-BB
(R&D Systems, Minneapolis, MN, USA) and 10 ng/ml
TGF-β (R&D Systems). We used the TGF-β1 isoform.
Media were changed every 2 days.
Small interfering RNA assay
To silence CD248 expression, SSc-MSC were transfected
with Silencer Select CD248 small interfering RNA
(siRNA; Life Technologies) [31] or with Silencer Select
nontargeting scrambled (scr) siRNA (Life Technologies)
using Lipofectamine™ 2000 reagent (Life Technologies).
The CD248 gene was identified to be transcribed from a
2557-bp single-exon gene [32, 33].
Transfection was performed according to the manu-
facturer’s instructions. Briefly, MSC were plated at 1 ×
104 cells/cm2 24 h prior to transfection. Cultures were
incubated for 24 h with 30 pmol of siRNA in 2 ml of
Opti-MEM (Life Technologies). After incubation, plates
were washed, and cells were allowed to recover in
growth conditions (1% FBS) supplemented with TGF-β
(10 ng/ml) and PDGF-BB (10 ng/ml).
Western blot analysis
MSC, derived from two EOS and two LSS patients, were
pelleted and lysed in lysis buffer (radioimmunoprecipita-
tion assay buffer; Cell Signaling Technology, Danvers,
MA, USA) for 30 min and cleared by centrifugation. The
protein concentration was calculated by using a bicincho-
ninic acid protein assay kit (EuroClone, Pero, Italy).
Proteins (40 μg) were separated by SDS-PAGE and trans-
ferred to nitrocellulose membranes. After blocking in 10%
nonfat milk in Tris-buffered saline/1% Tween 20 and
incubated with the primary antibodies α-SMA (Santa Cruz
Biotechnology, Dallas, TX, USA) and CD248 (Novus
Biologicals), horseradish peroxidase-conjugated secondary
antibodies (Cell Signaling Technology) were appropriately
used. The detection was performed using long-lasting
chemiluminescent substrate (EuroClone). All the signals
were quantified by normalizing to the β-actin signal (Santa
Cruz Biotechnology). Immunoreactive bands were ac-
quired using a ChemiDoc imaging system with Image Lab
software (Bio-Rad Laboratories, Hercules, CA, USA) and
quantified with densitometry using ImageJ software.
qRT-PCR analysis
Total RNA was extracted from MSC and whole bi-
opsy using NucleoSpin RNA (Macherey-Nagel, Düren,
Germany) and reverse-transcribed into complementary
DNA (cDNA) with the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA,
USA). The qRT-PCR was run in triplicate. Ki-67 and
GAPDH gene expression were assessed using commercial
TaqMan gene expression assay (Hs01032443_m1; Hs02
758991_g1, respectively). α-SMA, CD248, and β-actin
expression was performed by using SYBR Green kits
(Applied Biosystems). Primers were designed on the basis
of reported sequences in the National Center for Biotech-
nology Information PrimerBank [β-actin: 5′-CCTGGC
ACCCAGCACAAT-3′ (forward) and 5′-AGTACTCCG
TGTGGATCGGC-3′ (reverse); α-SMA: 5′-CGGTGCT
GTCTCTCTATGCC-3′ (forward) and 5′-CGCTCAGTC
AGGATCTTCA-3′ (reverse); CD248: 5′-AGTGTTATT
GTAGCGAGGGACA-3′ (forward) and 5′-CCTCTGGG
AAGCTCGGTCTA-3′ (reverse)]. Results were analyzed
after 45 cycles of amplification using the ABI 7500 Fast
Real Time PCR System (Applied Biosystems).
Statistical analysis
Prism 5.0 software (GraphPad Software, La Jolla, CA,
USA) was used for statistical analyses. Results are
expressed as median (range). Owing to the nonparamet-
ric distribution of our data, the Mann-Whitney U test
was used as appropriate for analyses. Statistical signifi-
cance was expressed by a p value < 0.05.
Results
CD248 expression in skin SSc
Our results show that CD248 is overexpressed in SSc
skin, and specifically in both EC and perivascular cells,
when compared with HC skin, as observed in Fig. 1.
Consistent with these findings, in whole SSc skin biop-
sies, CD248 mRNA expression was significantly in-
creased when compared with HC skin, as assessed by
qRT-PCR. Furthermore, in LSS skin, the CD248 mRNA
expression was significantly increased when compared
with EOS skin (Fig. 1g).
Interestingly, we observed that CD248 expression was
not limited only to the cells of blood vessels; also other
cells, proximal to microvessels, showed an increased ex-
pression of this marker (Fig. 1a–d, arrowheads). To bet-
ter understand our findings, we performed different
staining to identify the possible lineage of these cells,
and as shown in Fig. 2, these cells surrounding the
vascular trees coexpressed the CD90 marker, which is
highly expressed in undifferentiated MSC [34]. Of
interest, these CD90+/CD248+ cells were significantly
increased in SSc skin when compared with HC skin (Fig.
2). Finally, the number of these CD90+/CD248+ cells
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was significantly higher in LSS SSc skin (Fig. 2c and d)
than in EOS SSc skin (Fig. 2a and b).
TGF-β and PDGF-BB effects on CD248 expression in MSC
We investigated the functional role of CD248 in vitro in
the perivascular differentiation toward myofibroblasts, by
using MSC, a validated surrogate of perivascular cells [26].
Figure 3a shows that in SSc-MSC, CD248 mRNA expres-
sion levels were significantly higher than in HC-MSC
[CD248 mRNA levels in untreated [UT] SSc-MSC 1.32
(1.25–1.50) vs UT HC-MSC 0.96 (0.73–1.17); p < 0.0001].
Furthermore, in SSc-MSC, TGF-β induced a significant
decrease of CD248 mRNA expression levels when
compared with UT SSc-MSC [CD248 mRNA levels in
TGF-β SSc-MSC 0.74 (0.54–0.94) vs UT SSc-MSC 1.32
(1.25–1.50); p < 0.0001]. In HC-MSC, the TGF-β treat-
ment induced a significant reduction of CD248 mRNA ex-
pression levels when compared with UT cells [CD248
mRNA levels in TGF-β HC-MSC 0.07 (0.03–0.15) vs UT
HC-MSC 0.96 (0.73–1.17); p < 0.0001], although in
SSc-MSC, the levels of CD248 expression were always sig-
nificantly higher than in HC-MSC. On the contrary, no
CD248 mRNA modulation was observed by using
PDGF-BB, in both SSc- and HC-MSC [CD248 mRNA
levels in PDGF-BB SSc-MSC 1.69 (1.24–1.85) vs UT
SSc-MSC 1.32 (1.25–1.50); p = ns; CD248 mRNA levels in
Fig. 1 CD248 expression in skin of patients with systemic sclerosis (SSc). a, b Immunofluorescence staining of ten early-onset subset (EOS) SSc
skin samples. a CD248 (green) and von Willebrand factor (vWF) (red) staining. b Consecutive section stained with CD248 (green), α-smooth muscle
actin (α-SMA) (red). CD248 is expressed in endothelial cells (EC) and perivascular cells of EOS SSc skin vessels. The arrowheads show CD248+ cells
localized close to microvessels. c and d Immunofluorescence staining of ten long-standing subset (LSS) SSc skin samples. c CD248 (green) and
vWF (red) staining. d Consecutive section stained with CD248 (green) and α-SMA (red). CD248 is expressed in EC and perivascular cells of LSS SSc
skin vessels. The arrowheads show CD248+ cells localized close to microvessels. e and f Immunofluorescence staining of ten healthy control
subject (HC) skin samples. Microphotographs show (e) CD248 (green) and vWF (red) staining and (f) consecutive section stained with CD248
(green) and α-SMA (red). Weak expression of CD248 may be observed in EC and pericytes of HC skin vessels. Negative control samples were
obtained by omitting the primary antibody. Original magnification × 20. g qRT-PCR of CD248 messenger RNA (mRNA) levels in ten EOS-SSc skin,
ten LSS-SSc skin, and ten HC-skin samples. In SSc-skin, CD248 mRNA expression levels are always significantly higher than in HC mesenchymal
stem cells. CD248 mRNA expression is significantly higher in LSS-SSc skin than in EOS-SSc skin. * p = 0.01, *** p < 0.0001
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PDGF-BB HC-MSC 0.85 (0.72–1.0) vs UT HC-MSC 0.96
(0.73–1.17); p = n.s.].
TGF-β induces an increase of α-SMA in MSC
TGF-β treatment induced a significant increase of
α-SMA mRNA expression in both SSc- and HC-MSC
when compared with UT cells [α-SMA mRNA levels in
TGF-β SSc-MSC 11.90 (9.36–15.87) vs UT SSc-MSC
7.53 (6.94–7.94); p < 0.0001; α-SMA mRNA levels in
TGF-β HC-MSC 1.66 (1.14–2.48) vs UT HC-MSC 1.05
(0.84–1.18); p < 0.0001]. On the contrary, PDGF-BB
treatment induced a significant decrease of α-SMA when
compared with UT cells, in both HC- and SSc-MSC
[α-SMA mRNA levels in PDGF-BB SSc-MSC 1.84
(1.52–2.01) vs UT SSc-MSC 7.53 (6.94–7.94); p < 0.0001;
α-SMA mRNA levels in PDGF-BB HC-MSC 0.54 (0.24–
0.70) vs UT HC-MSC 1.05 (0.84–1.18); p < 0.0001] (Fig.
3b). Western blot analysis confirmed the results of gene
expression (Fig. 3d).
TGF-β and PDGF-BB effects on cell proliferation in MSC
To assess the proliferative ability of our cells, we per-
formed qRT-PCR for Ki-67 gene expression, a molecule
considered to be associated with active proliferation. We
observed that TGF-β treatment induced a significant de-
crease of Ki-67 in both SSc- and HC-MSC; on the con-
trary, PDGF-BB induced a significant increase of Ki-67
when compared with UT cells in both SSc- and
HC-MSC [Ki-67 mRNA levels in TGF-β SSc-MSC
0.0066 (0.0013–0.016) vs UT SSc-MSC 0.16 (0.08–
0.23); p < 0.0001; Ki-67 mRNA levels in TGF-β
HC-MSC 0.64 (0.54–0.84) vs UT HC-MSC 1.04 (0.85–
1.26); p < 0.0001; Ki-67 mRNA levels in PDGF-BB
SSc-MSC 0.63 (0.52–0.81) vs UT SSc-MSC 0.16 (0.08–
Fig. 2 CD248+/CD90+ mesenchymal stem cells (MSCs) surrounding the vessels in systemic sclerosis (SSc) skin. a, b Immunofluorescence staining
of ten early-onset subset (EOS) SSc skin samples. Microphotographs show (a) CD248 (green) and von Willebrand factor (vWF) (red) staining and (b)
consecutive section stained with CD248 (green) and CD90 (red). c and d Immunofluorescence staining of ten long-standing subset (LSS) SSc skin
samples. Microphotographs show (c) CD248 (green) and vWF (red) staining and (d) consecutive section stained with CD248 (green) and CD90
(red). e and f Immunofluorescence staining of ten healthy control subject (HC) skin samples. Microphotographs show (e) CD248 (green) and vWF
(red) staining and (f) consecutive section stained with CD248 (green) and CD90 (red). Negative controls were obtained by omitting the primary
antibody. Original magnification × 20. g Median number of CD90+/CD248+ cells. The number of CD90+/CD248+ cells is significantly higher in
LSS-SSc skin than in EOS-SSc skin. Any dot plot is representative of the median cell count per 5 high-power fields (HPF) (× 40) for each patient.
* p = 0.02, *** p = 0.0001
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Fig. 3 Transforming growth factor (TGF)-β and platelet-derived growth factor (PDGF)-BB effects on CD248, α-smooth muscle actin (α-SMA), and
Ki-67 expression in systemic sclerosis (SSc) mesenchymal stem cells (MSCs). a qRT-PCR of CD248 messenger RNA (mRNA) levels in ten SSc-MSC
(five early-onset subset [EOS] and five long-standing subset [LSS]) and ten healthy control subject (HC) MSC samples. In SSc-MSCs, CD248 mRNA
expression levels are always significantly higher than in HC-MSCs. b qRT-PCR of α-SMA mRNA levels in ten SSc-MSCs (five EOS and five LSS) and
ten HC-MSCs. In SSc-MSCs, the α-SMA mRNA levels are always significantly higher than in HC-MSCs. In both SSc- and HC-MSCs, TGF-β treatment
induces a significant increase of α-SMA mRNA expression compared with untreated (UT) cells. On the contrary, PDGF-BB treatment induces a
significant decrease of α-SMA compared with UT cells in both HC- and SSc-MSCs. c qRT-PCR of Ki-67 mRNA levels in ten SSc-MSCs (five EOS and
five LSS) and ten HC-MSCs. In both SSc- and HC-MSCs, TGF-β treatment induces a significant decrease of Ki-67; on the contrary, PDGF-BB induces
a significant increase of Ki-67 when compared with UT cells in both SSc- and HC-MSCs. The TGF-β isoform used is TGF-β1. Any single dot in the
figure represents the median of triplicate experiments for each patient ** p = 0.0002, *** p = 0.0001. d Western blot analyses performed in four
SSc-MSCs (two EOS and two LSS) and four HC SSc-MSCs confirmed the results observed by qRT-PCR analyses. Pictures are representative of all
experiments. e and f Densitometric analysis of (e) CD248 protein bands and (f) α-SMA protein bands. The values were expressed as protein
relative quantification/β-actin relative quantification. * p = 0.02
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0.23); p < 0.0001; Ki-67 mRNA levels in PDGF-BB
HC-MSC 2.08 (1.63–2.63) vs UT HC-MSC 1.04 (0.85–
1.26); p < 0.0001] (Fig. 3c).
CD248 silencing interferes with PDGF-BB and TGF-β
signaling in SSc-MSC
To address the role of CD248 in this cytokine network,
we inactivated CD248 gene product in SSc-MSC by
transfecting these cells with CD248-siRNA or scr-siRNA.
CD248-siRNA efficiently knocked down CD248 mole-
cules in SSc-MSC (> 71%), and, after silencing, TGF-β
was unable to modulate the CD248 expression (Fig. 4a).
Figure 4b shows that in CD248 silenced MSC, TGF-β
stimulation did not induce α-SMA mRNA upregulation.
Furthermore, in the same cells, PDGF-BB was unable to
induce an increased expression of Ki-67 gene levels
when compared with scr-siRNA-treated MSC (Fig. 4c).
Western blot analysis confirmed the results of gene ex-
pression (Fig. 4d).
Discussion
This report is the first, to the best of our knowledge, in-
dicating that CD248, first identified as a tumor vascular
endothelial antigen [35] and considered a key molecule
of myofibroblast generation, is deeply involved in TGF-β
and PDGF-BB signaling transduction during the fibrosis
associated with SSc and that its inhibition strongly inter-
feres with the profibrotic pathways of these two cyto-
kines. Recently, CD248 has been considered as a marker
of stromal fibroblasts, pericyte subsets, and human MSC
[36, 37], and in the experimental model of fibrosis, after
UUO, a significant upregulation of CD248 was observed
[3]. On the contrary, CD248−/− mice were protected
from renal fibrosis and capillary rarefaction, probably
Fig. 4 Systemic sclerosis (SSc) mesenchymal stem cells (MSCs) silenced by small interfering RNA (siRNA) CD248. a qRT-PCR of CD248 in ten SSc-MSCs
(five early-onset subset [EOS] and five long-standing subset [LSS]) transfected with specific CD248-siRNA or scrambled (scr)-siRNA. Cells transfected
with CD248-siRNA show a decreased expression of the CD248 gene compared with cells transfected with scr-siRNA. In SSc-MSCs treated with
scr-siRNA, the transforming growth factor (TGF)-β stimulus induces a significant decrease of CD248 expression. On the contrary, in CD248-siRNA cells,
TGF-β is unable to modulate CD248 mRNA expression. b qRT-PCR of α-SMA in ten SSc-MSCs (five EOS and five LSS) transfected with specific CD248-
siRNA or scr-siRNA. In SSc-MSCs treated with scr-siRNA, the TGF-β stimulus induces a significant increase of α-SMA mRNA expression. On the contrary,
in CD248-siRNA cells, TGF-β is unable to modulate α-SMA mRNA expression. c qRT-PCR of Ki-67 in ten SSc-MSCs (five EOS and five LSS) transfected
with specific CD248-siRNA or scr-siRNA. In SSc-MSCs treated with scr-siRNA, the PDGF-BB stimulus induces a significant increase of Ki-67 mRNA
expression. On the contrary, in CD248-siRNA cells, PDGF-BB is unable to modulate Ki-67 mRNA expression. The TGF-β isoform used is TGF-β1. Any
single dot in the figure represents the median of triplicate experiments for each patient. *** p = 0.0001. d Western blot analyses performed in four
SSc-MSCs (two EOS and two LSS) confirmed the results observed by qRT-PCR analyses. Pictures are representative of all experiments. e and f
Densitometric analysis of (e) CD248 protein bands and (f) α-SMA protein bands. The values were expressed as protein relative quantification/β-actin
relative quantification. * p = 0.02
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inhibiting pericyte differentiation toward α-SMA+ inter-
stitial myofibroblasts and preventing vascular instability
and collagen production [3]. Furthermore, it has been
reported that CD248 expressed on pericytes can pro-
mote EC apoptosis, probably impairing the cross-talk
between EC integrins and vascular endothelial growth
factor (VEGF) receptor 2, leading to the attenuation of
VEGF signaling [38]. On these bases, CD248 may be
considered a key target in those pathologic processes in
which vascular damage and fibrosis are strongly joined
in SSc.
In our present study, we chose to include in the pa-
tient cohort only patients affected by the Scl70+ diffuse
form of the disease, because this subset rapidly pro-
gresses from vascular damage to fibrosis and may be
considered a good “human model” to evaluate the link
between vascular damage and fibrosis. In fact, it is well
known that anti-Scl70 antibody is one of the typical
autoimmune markers in SSc, occurring in 60.8% of cases
of diffuse SSc and 23.4% of cases of limited SSc [39].
The presence of anti-Scl70 antibody is associated with
severity of the disease, decreased survival [40], and evi-
dence of pulmonary fibrosis [41]. We observed that
CD248 was constitutively overexpressed on SSc cells de-
rived from mesenchymal lineage. In SSc skin, we ob-
served that CD248 was expressed on stromal fibroblasts
and perivascular cells located in close proximity to the
vessel, when compared with healthy skin, and the num-
ber of CD248+ cells significantly increased over time.
Furthermore, in LSS-SSc biopsy, the CD248 mRNA ex-
pression of whole biopsy was significantly increased
when compared with EOS-SSc. Of note, IF showed that
the CD248+ cells coexpressed CD90, a molecule highly
expressed in all the undifferentiated MSC [42, 43]. Cur-
rently, although we do not have a single cell marker cap-
able of defining MSC, available literature suggests that
CD90, which is highly expressed in all MSC, regardless
of the source, may be considered a good marker to iden-
tify undifferentiated MSC [34]. The increased CD248 ex-
pression in perivascular cells of patients with SSc highly
coexpressing the stem marker CD90 may suggest that in
these MSC, both the profibrotic machinery and cells’ dif-
ferentiation toward myofibroblasts may be activated.
Furthermore, our results showed that increased
CD248 expression may be observed also in EC of SSc
skin biopsies. It has been reported that CD248 may be
expressed by endothelial progenitor cells [44] and tumor
EC, together with pericytes and tumor-associated fibro-
blasts, during active cancer angiogenesis [38, 45]. It has
been proposed that CD248 expressed by EC may inter-
act with ECM proteins as well as tumor stromal cells to
promote vascular invasion and migration [46]; in fact,
CD248 expression was induced in EC when cultured in
Matrigel, suggesting that endosialin could be induced in
EC exposed to a complex extracellular environment
[46]. In our setting, we hypothesize that SSc-EC may ex-
press CD248 as a compensatory mechanism to support
angiogenesis in the context of a disease characterized by
progressive desertification of vascular tree.
We investigated the functional role of CD248 in vitro
in the perivascular differentiation toward myofibroblasts
by using MSC, a validated surrogate of perivascular cells
[26, 47]. Although the possible role of the CD248 mol-
ecule in SSc pathogenesis is largely unknown, it has been
reported that this molecule is involved in the fibroproli-
ferative process by modulating the PDGF-BB pathway
[21] and collaborating with the TGF-β pathway to in-
duce α-SMA expression [48]. In HC cells, TGF-β in-
duced significantly decreased of CD248 when compared
with UT cells. On the contrary, SSc-MSC displayed sig-
nificantly higher CD248 expression than HC cells in
both TGF-β-stimulated and unstimulated cultures. Re-
cently, it has been shown that TGF-β strongly sup-
presses CD248 expression in healthy murine fibroblast
cell lines; on the contrary, during cancer, where signifi-
cantly higher CD248 levels are reported, mirroring what
we observed in our cells, TGF-β failed to downregulate
CD248 expression [49]. Although TGF-β is not a pro-
moter of CD248 expression, CD248 may collaborate
with TGF-β to induce α-SMA, possibly via downregula-
tion of Notch3 [9, 12] and upregulation of interleukin 6
(IL6), C-C motif chemokine ligand 2 (CCL2), TGF-β1,
and TGF-βR1 [48]. In fact, it has been reported that
Notch3 may prevent the TGF-β1 induction of α-SMA,
working as a molecular brake on smooth muscle gene
transcription [50]. Furthermore, IL6, CCL2, TGF-β1, and
TGF-βR1, activated by CD248, may strongly stimulate
α-SMA [51]. Thus, we may hypothesize that CD248
overexpression in SSc-MSC may play its profibrotic role,
exacerbating the TGF-β effects [52], by removing the
Notch3 control and promoting α-SMA expression by its
own downstream mediators. In fact, after silencing
CD248, cells were unable to induce α-SMA expression
after TGF-β stimulus, thus confirming the key role of
CD248 in increasing the TGF-β effects in SSc-MSC.
To date, conflicting results have been reported in avail-
able literature concerning the expression of different
smooth muscle genes during fibroblast proliferation and
activation. Transcript levels of Sm22 are elevated in fibro-
blasts derived from mice lacking the cytoplasmic domain
of CD248 [12], and CD248 knockdown did not affect the
in vitro expression of α-SMA in normal human lung fibro-
blast [31]. On the contrary, in in vitro cultured human
pericytes, the ability of TGF-β to induce α-SMA expres-
sion was lost in the CD248-specific siRNA-transfected pri-
mary human brain vascular pericytes, suggesting that
α-SMA induction is CD248-dependent [53]. Furthermore,
in an experimental model of liver fibrosis, the total liver
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mRNA of collagen and α-SMA was reduced in CD248-de-
ficient mice compared with wild-type mice [19], and in a
model of renal fibrosis, no increase of α-SMA molecule
was observed in CD248-deficient mice [8]. These discrep-
ancies may be partially explained by the different experi-
mental models, the differences in cell manipulation, the
intensity and quality of stimuli, and the different levels of
efficacy in CD248 silencing.
To assess the contribution of CD248 in modulating
the proliferative ability of SSc-MSC, we evaluated the
expression of Ki-67 gene expression, which strongly cor-
relates with cellular proliferation [19]. PDGF-BB induced
a significant increase of Ki-67 levels when compared
with UT cells in both HC- and SSc-MSC.
The role of CD248 in PDGF-BB signaling has been
studied in human pericytes and hepatic stellate cells
(HSC), commonly considered the precursors of septal
myofibroblasts in liver fibrosis. PDGF-BB currently is
considered one of the most potent HSC mitogens
known, and it plays a key regulatory role in HSC prolif-
eration during hepatic fibrogenesis [19]. It has been pro-
posed that CD248 regulates the PDGF-BB pathway, thus
controlling cell proliferation [54].
After CD248 silencing, we observed a strong inhibition
of PDGF-BB-mediated cell proliferation, suggesting that
this process is under CD248 control, thus decreasing the
myofibroblast accumulation and confirming previous re-
ports [23] in which primary renal fibroblasts isolated
from CD248-knockout mice displays both decreased cell
proliferation and reduced collagen secretion when com-
pared with wild-type mice. Currently, it is still unclear
how CD248 may modulate this proliferative signal: via
the matrix-binding properties of CD248 and/or by the
well-known ability of this molecule to potentiate
PDGF-BB signaling. Recent studies in hepatic fibrosis,
however, have provided evidence that HSC CD248−/−
display normal levels of PDGF receptors, suggesting
that the antiproliferative effect of CD248−/− HSCs is
not mediated through the modulation of PDGF recep-
tor expression [19].
Conclusions
Our study shows that SSc perivascular cells overexpress
CD248, which is involved in SSc pericyte transition to-
ward myofibroblasts, and CD248 silencing may prevent
pericyte-to-myofibroblast transition, proliferation, vascu-
lar instability, and tissue fibrosis. Taken together, our
data suggest that targeting CD248 expression may be
considered a potential target in order to block tissue fi-
brosis and vascular desertification during SSc.
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